Portola Pharma (PTLA) Misses Q4 EPS by 23c

Portola Pharma (NASDAQ: PTLA) reported Q4 EPS of ($1.34), $0.23 worse than the analyst estimate of ($1.11). Revenue for the quarter came in at $15.3 million versus the consensus estimate of $10.94 million.

For earnings history and earnings-related data on Portola Pharma (PTLA) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• RBC Capital Upgrades GEA Group AG (G1A:GR) (GEAGY) to Outperform
• SWBI beats estimates by 71%, GEO nears 52-week high on policy tailwinds